A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE STUDY TO COMPARE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-04965842 IN ADULT SUBJECTS WITH MILD AND MODERATE HEPATIC IMPAIRMENT RELATIVE TO SUBJECTS WITH NORMAL HEPATIC FUNCTION
Phase of Trial: Phase I
Latest Information Update: 24 May 2019
Price : $35 *
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 20 May 2019 Status changed from recruiting to completed.
- 08 May 2019 Planned End Date changed from 1 Apr 2019 to 30 Apr 2019.
- 08 May 2019 Planned primary completion date changed from 1 Apr 2019 to 30 Apr 2019.